[Comment] Remission in chronic cough: an achievable target?

Refractory chronic cough (RCC), defined as a persistent cough for more than 8 weeks despite adequate treatment of underlying comorbidities, is increasingly acknowledged as a standalone clinical disease with a neuropathic aetiology.1 For clinicians, decades of therapeutic nihilism have been replaced with hope for the future, given the advances in therapeutics. The first targeted medication, gefapixant, has been licensed in the EU, UK, Switzerland, and Japan and has proven efficacy, with indications of sustained improvement even after discontinuation.